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kadherin-1 (LA1) is a small molecule agonist that enhances CD11b/CD18-dependent cell adhesion to its ligand ICAM-1. Here,
we used single-molecule force spectroscopy to investigate the biophysical mechanism by which LA1-activated CD11b/CD18
mediates leukocyte adhesion. Between the two distinct populations of CD11b/CD18:ICAM-1 complex that participate in cell
adhesion, the cytoskeleton(CSK)-anchored elastic elements and the membrane tethers, we found that LA1 enhanced binding
of CD11b/CD18 on K562 cells to ICAM-1 via the formation of long membrane tethers, whereas Mn2þ additionally increased
ICAM-1 binding via CSK-anchored bonds. LA1 activated wild-type and LFA1/ neutrophils also showed longer detachment
distances and time from ICAM-1-coated atomic force microscopy tips, but significantly lower detachment force, as compared
to the Mn2þ-activated cells, confirming that LA1 primarily increased membrane-tether bonds to enhance CD11b/CD18:ICAM-1
binding, whereas Mn2þ induced additional CSK-anchored bond formation. The results suggest that the two types of agonists
differentially activate integrins and couple them to the cellular machinery, providing what we feel are new insights into signal
mechanotransduction by such agents.INTRODUCTIONAdhesion to neighboring cells, extracellular matrix, and li-
gands is fundamental to a majority of biological cells. Mod-
ulation of the process of cell adhesion regulates a variety of
functions of these cells and is mediated by an array of cell
adhesion receptors that are expressed on cell surfaces. Integ-
rins are a family of ab heterodimeric type I adhesion recep-
tors that are present in all mammalian cells and mediate
diverse cellular functions. Among them, the b2 family of in-
tegrins is primarily expressed on the surface of leukocytes
and consists of four members that share a common b-chain
(CD18) and distinct a-chains (CD111a, CD11b, CD11c, and
CD11d). The b2 integrin CD11b/CD18 (also known as
Mac-1, aMb2, and CR3) is expressed primarily in the cells
of the innate immune system (including neutrophils, macro-
phages, and dendritic cells) (1–3). ICAM-1 (CD54) is a
member of the immunoglobulin family that is expressed
on the surface of vascular endothelial cells and is signifi-
cantly upregulated upon an inflammatory stimulus (4),
where it mediates migration and tissue recruitment of leuko-
cytes from circulation. Leukocyte emigration is a multistep
process that includes the steps of cell tethering, slow rolling,
firm adhesion, crawling, and transmigration across the endo-
thelial cell barrier (5). Leukocyte rolling along the walls of
microvessels involves a generation of thin, long membrane
tethers that are not linked to the leukocytic cytoskeleton
and that stabilize leukocyte rolling (6,7). Integrin CD11b/
CD18, among its various functions, mediates leukocyteSubmitted July 8, 2013, and accepted for publication October 18, 2013.
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0006-3495/13/12/2517/11 $2.00emigration from circulation to the inflamed tissue by bind-
ing to ICAM-1 (8–10), one of its >30 physiologic ligands,
making it an important therapeutic molecular target for
reducing the influx of inflammatory leukocytes into tissues
and, thus, for the development of antiinflammatory drugs
(11). Indeed, studies over the years have targeted b2 integ-
rins on leukocytes, as well as their ligand ICAM-1, with
antagonists that block adhesion of leukocytes to endothelial
cell surfaces (12–15). However, a majority of such adhesion
blocking agents failed in various human clinical trials
(16–19), suggesting a need for alternative ways to reduce
leukocyte binding and recruitment into tissues as a way to
affect inflammation. We recently described novel small
molecule allosteric agonists of CD11b/CD18 (termed
leukadherins) that enhance, rather than inhibit, CD11b/
CD18-dependent cell adhesion (20). Leukadherin-mediated
increase in cell adhesion significantly reduces leukocyte cell
migration in vitro and in vivo. It also significantly reduces
tissue influx of leukocytes and led to amelioration of inflam-
matory injury in multiple experimental models (20). This
suggests that integrin activation via allosteric agonists
(i.e., a type of agonists that modulate the structure and activ-
ity of a protein (integrin) by binding to a site distal from the
site of activity or ligand binding) may represent, to our
knowledge, a novel and effective approach for reducing
leukocyte emigration and tissue recruitment and for the
development of next generation antiinflammatory therapeu-
tic agents.
However, not all integrin agonists behave in the same
way. We recently found that CD11b/CD18 activation
with many other agonists, such as the known agonist
Mn2þ ions or the CD11b activating antibodies, induceshttp://dx.doi.org/10.1016/j.bpj.2013.10.020
2518 Celik et al.outside-in signaling in cells, whereas Leukadherin 1 (LA1)
does not (21), suggesting that there may be differences in
the way different agonists activate and transmit signal
from the integrin extracellular domains to the cytoplasm.
Our previous data also suggest that, because binding of
different types of agonists to the extracellular domains of in-
tegrins produces different intracellular signaling outputs and
because the extracellular domains are linked to the intracel-
lular signaling machinery via the cytoskeleton, integrin acti-
vation with different types of agonists may couple them
differently to the cytoskeletal protein machinery. Published
data with some ligand-mimetic integrin antagonists also
show binding mediated integrin activation (thus, suggesting
that these agents function as agonists) and produces outside-
in signaling in cells, leading to serious side effects (22–25),
supporting our hypothesis. We reasoned that, because integ-
rins couple to cellular cytoskeleton to transduce mechano-
signals, understanding the biophysical nature of forces
generated upon integrin activation with various agonists
would provide useful insights into how different integrin
agonists regulate intracellular signaling and cell function.
Atomic force microscopy (AFM)-based single-cell force
spectroscopy (SCFS) can be used to quantitatively study
cell adhesion to extracellular matrix ligands (26). Here,
we used such AFM-based SCFS measurements to quantita-
tively determine the differences in coupling of CD11b/
CD18 to the cytoskeletal machinery when activated with a
known agonist (Mn2þ) versus the novel, to our knowledge,
agonist LA1. We also quantified the agonist-induced
changes in adhesive strength of CD11b/CD18 expressing
cells and used that information to develop a mechanism of
how different integrin agonists may differentially regulate
cellular behavior. We found that Mn2þ increased cell adhe-
sion primarily via cytoskeleton-anchored integrin bonds,
whereas LA1 primarily increased the occurrence of mem-
brane-tethered bonds, suggesting that the two types of
agonists may differentially mediate the increase in cellular
adhesivity via integrins. Such knowledge should be helpful
in designing new integrin agonists in the future.MATERIALS AND METHODS
Reagents and antibodies
ICAM-1/Fc chimera (referred to as ICAM-1 hereafter) was purchased from
R&D Systems (Minneapolis, MN). Fluorescent cell surface labeling re-
agent BacMam 2.0 CellLight Plasma Membrane-GFP was obtained from
Life Technologies (Carlsbad, CA). Highbind 384-well plates were obtained
from Corning (Corning, NY). Nonfat milk was obtained from Bio-Rad. All
cell culture reagents were purchased from Life Technologies and Medi-
atech. Fetal bovine serum (FBS) was purchased from Atlanta Biologicals.
The antibiotic G418 was purchased from Invivogen and the chemical re-
agents were obtained from Fluka. For all experimental assays, a stock solu-
tion of agonist LA1 (20) was prepared by dissolving the compound in
dimethylsulfoxide (DMSO) at a concentration of 10 mM. LA1 was used
at a final concentration of 15 mM in the assays by diluting in the assay
buffer. The final concentration of DMSO in the assay was ~1%. To controlBiophysical Journal 105(11) 2517–2527for any DMSO-related effects, DMSOwas also included in non-LA1 exper-
iments and was maintained at 1% in all assay buffers.Animals
Wild-type (WT) C57BL/6J mice (B6) and the B6 CD11a/ (LFA-1/,
Jax 5257) (27) animals were purchased from the Jackson Laboratories.
Animal care and procedures were approved by the Institutional Animal
Care and Use Committee (IACUC) and were performed in accordance
with institutional guidelines.Cells and cell lines
K562 cells (ATCC) stably transfected with plasmid encoding WT CD11b/
CD18 (K562 CD11b/CD18 cells) have been described previously (28,29)
and were maintained in Iscove’s modified Dulbecco’s medium (IMDM)
supplemented with 10% FBS and G418 (0.5 mg/ml).Cell adhesion assays
Cell adhesion assays using K562 CD11b/CD18 cells or with WTor LFA/
neutrophils were performed as previously described (20,30) and used
immobilized ICAM-1 as the ligand of CD11b/CD18. Briefly, 384-well
microtiter plates (Corning) were coated with ICAM-1 (0.35 mg/mL) in
phosphate buffered saline (PBS), pH 7.4 containing 1 mM each of Ca2þ
and Mg2þ ions (PBS2þ buffer) by incubating overnight at 4C. The nonspe-
cific sites were subsequently blocked with 1% nonfat milk in Tris buffered
saline (TBS), pH 7.4, for 1 h at room temperature before the K562 cell
adhesion assay, or with TBS containing 1% gelatin before the neutrophil
cell adhesion assay. For the adhesion assay, 30,000 cells were added to
each well. For the K562 cell-based assays, cells were suspended in Tris
Buffered Saline (TBS), pH 8 containing 1 mM each of Ca2þ and Mg2þ
ions (TBS2þ buffer) and incubated in the presence of various agents in
the ligand-coated wells of the microtiter plate for 30 min at 37C. For
the neutrophil adhesion assays, neutrophils from 8- to 10-week old WT
B6 and LFA-1/ mice were isolated from thioglycollate-stimulated peri-
tonea according to literature protocols (20). Neutrophils were suspended
in serum free medium (IMDM) and incubated with leukadherins in the
ligand-coated wells for 10 min at 37C. The assay plates with either cell
type were then gently inverted and kept in the inverted position for
30 min at room temperature to dislodge the nonadherent cells. The remain-
ing adherent cells were fixed using 4% formaldehyde and quantified by
imaging microscopy as previously described (20). As previously described
(28,30), the input cell number for these imaging-based analyses was calcu-
lated by counting the cells adherent in the uncoated microtiter plate wells
(which nonspecifically binds almost all input cells) and was used to
normalize the data. Assays were performed in triplicate wells. Data reported
are from one of at least three independent experiments.Chemotaxis assay and time-lapse video
microscopy
Neutrophil chemotaxis on planar surfaces was performed using Zigmond
chambers (Neuro Probe) on acid-cleaned or ICAM-1-coated glass cover-
slips, according to the protocol described previously (31,32). Briefly, neu-
trophils were preincubated on a glass coverslip in a humidified chamber
in the cell culture media (RPMI 1640 containing 1% FBS) in the presence
of agonists Mn2þ ions (0.1–1 mM) or LA1 (15 mM), for 5–10 min and the
coverslip was then placed on top of Zigmond chambers. A formyl-Met-Leu-
Phe (fMLP) (Sigma, F3506) gradient was created in between the Zigmond
chambers by placing the assay buffer in one well of the chamber and fMLP
(10 mM) containing assay buffer (RPMI 1640 containing 1% FBS) in the
other well. The migration of WT or LFA1/ neutrophils toward fMLP
CD11b Agonists Induce Membrane Tethers 2519was recorded at 5- to 30-s intervals for a period of 25 min using either a
Nikon Eclipse 90i microscope or a Leica DMI16000 deconvolution micro-
scope, as previously described (20). Images with the Nikon microscope
were acquired using a Nikon DS camera with a PLAN APO 20 differen-
tial interference contrast microscopy objective and was acquired using the
Nikon Imaging software. Leica differential interference contrast images
were acquired using an HCX PL APO 40/0.75 NA objective and a
DCF360FX camera driven by LAS-AF software. The neutrophil migration
data were analyzed using ImageJ software (NIH) with manual cell tracking
using the chemotaxis and migration tool plugins (Ibidi) for ImageJ. Data
from 75 to 100 neutrophils were quantified under each condition and
from at least three independent experiments.AFM force measurements
AFM was used to control the relative position of the interacting molecules
via expansion or contraction of the 90 mm closed loop piezoelectric trans-
lator (P-841.60; Physik Instrumente, Waldbronn, Germany). Sharp cantile-
vers were used for a single set of ~100 measurements and all the
measurements were carried out at 25C. Force measurements were carried
out on a custom-built AFM (33) using Si3N4 cantilevers with a nominal
spring constant of 0.02 N/m (MLCT-AUHW; Veeco Probes, Santa Barbara,
CA). To prepare the ICAM-1 functionalized AFM cantilevers, ultraviolet-
irradiated cantilevers were silanized with 3-aminopropyltriethoxysilane
solution in ethanol for 10 min. After incubation of the cantilevers with
0.1% glutaraldehyde for 30 min, they were washed in PBS and incubated
with ICAM-1 (2.5 mg/mL) for 45 min at room temperature. The cantile-
vers were then washed with PBS to remove unbound ICAM-1 and incu-
bated with 1% bovine serum albumin for 45 min to block nonspecific
adhesion sites. Typically, cantilevers were functionalized with ICAM-1
on the day of measurements and 3–5 different cantilevers were used for
each test condition. To obtain consistent results over many days and given
that the cantilevers prepared in different preparation batches could have
different ligand densities, the AFM cantilevers prepared in the same batch
were used to obtain data from different experimental conditions. Cantile-
vers were individually calibrated by thermal fluctuation analysis according
to the method of Hutter and Bechhoefer (26). The force acting between
the molecules was derived from the deflection of the AFM cantilever,
which was monitored by reflecting a focused laser beam off the back of
the cantilever into a 2-segment photodiode. After calibration, cells were
deposited on the petri dish (Falcon 351008) coated with poly-L-lysine
(0.1 mg/mL, 16 h incubation at 4C) and allowed to immobilize for
5 min. The AFM measurement buffer consisted of TBS (10 mM) with
0.1% bovine serum albumin, and 1% DMSO and the various agonists
were added to the medium before each assay. A typical force measurement
began with lowering the cantilever onto the substrate where adhesive inter-
action took place between the cell and the functionalized tip. After a
specified interaction time, the cantilever was subsequently retracted until
complete detachment from the cell surface occurred. A total of 25 force-
distance (F-z) curves were acquired for each experimental condition by
lowering the tip onto the cell at the rate of 3.75 mm/s, maintaining contact
for 2 s, and subsequently retracting the cantilever at the same speed
(3.75 mm/s). The average indentation force was ~1 nN. Curves were
obtained from at least nine cells under the same condition. The experi-
ments for each condition typically lasted 30 min and never longer than
1 h. The work of detachment was derived from integrating the adhesive
force over the distance traveled by the cantilever up to the point of the
last bond rupture or complete cellular detachment. The detachment time
was derived from detachment displacement times the retraction speed of
the cantilever.
For the AFM analysis, we collected 15–20 force curves per each cell
(thus, we obtained >100 measurements for each condition). For analysis,
however, we used nine as the n value because the variation between cells
was higher than the force curves collected for each cell. Therefore, instead
of using a single cell and high number of force curves, say 100, weincreased the number of cells to nine to have a better distribution and a
better representative of the adhesion events.Immunofluorescence microscopy
To visualize the long tethers, K562 CD11b/CD18 cells were transduced to
express a membrane-bound marker conjugated to a green fluorescent
protein (GFP) using the BacMam 2.0 CellLight Plasma Membrane-GFP
system (Life Technologies). K562 CD11bCD18 cells were suspended in
serum-free IMDM containing LA1 (15 mM) and were placed in glass
bottom dishes (Wilco Wells; Amsterdam, Netherland) coated with
ICAM-1. After 5 min, a bare AFM cantilever was used to displace the
cell laterally. Confocal images of live cells were recorded with a scanning
laser confocal microscope (Nikon A1R) system using a 60X oil immersion
objective (N.A. 1.4) at 25C. Z-stacks were generated from 0.2–0.5-mm
thick serial sections. Maximum projection reconstructions from z-stacks
were performed using Nikon’s NIS-Elements image acquisition software.
Imaging of the cells showed long membrane tethers when a mechanical
force was applied to displace the cells activated with LA1. The images pre-
sented are representative of at least 20 cells analyzed for each condition
from at least three independent experiments.Statistical analysis
Data were analyzed using GraphPad Prism and compared with the Student’s
t-test or by one-way ANOVAwith posthoc analysis, where appropriate. P<
0.05 was considered statistically significant.RESULTS
Leukadherins increase CD11b/CD18-dependent
cell adhesion to ICAM-1 and reduce deadhesion
We recently described integrin activation to be a useful
mechanism for the development of novel antiinflammatory
agents that reduce recruitment of inflammatory immune
cells into tissues by increasing integrin CD11b/CD18-
dependent cell adhesion to immobilized ligands (20,28).
We identified a group of small molecule agonists targeting
integrin CD11b/CD18, which we termed leukadherins
(20,28,34). Among them, LA1 (Fig. 1 A) showed high affin-
ity for CD11b/CD18 and increased cell adhesion to various
ligands by binding to an allosteric pocket of the ligand-bind-
ing aA-domain (also known as aI-domain) of CD11b
(CD11bA-domain, Fig. 1 B) (20). Increased cellular adhe-
sion due to LA1-binding to CD11b/CD18 also resulted in
significantly decreased cell migration. However, the me-
chanics of how LA1-mediated allosteric activation of
CD11bA-domain modulates cellular adhesion and migra-
tion are not known. Here, we used SCFS to quantitatively
investigate the biomechanical effects of LA1-mediated
CD11b/CD18 activation on live cells.
First, we examined the relative increase in cell adhesion
to immobilized physiologic ligand ICAM-1 that is mediated
by known integrin agonist Mn2þ ions (35,36) and our novel
allosteric agonist LA1 using K562 cells stably expressing
WT CD11b/CD18 (K562 CD11b/CD18), which have
full capacity and the machinery to link integrins to theBiophysical Journal 105(11) 2517–2527
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FIGURE 1 LA1 increases adhesion of integrin CD11b/CD18 to ICAM-1.
(A) Chemical structure of LA1. (B) A cartoon showing a computationally
generated model for LA1 (gray stick model) bound aA-domain (red ribbon)
of the integrin CD11b/CD18. The metal ion (blue sphere) in the metal ion-
dependent adhesion site (MIDAS) and the strands lining the activation
sensitive allosteric site in aA are also labeled (F, a7). (C) A histogram
showing relative adhesion of K562 CD11b/CD18 cells to immobilized
ICAM-1 (as a percent of input cell number) in the presence of EDTA
(10 mM), physiologic Ca2þ and Mg2þ ions (1 mM each, control), the
nonselective integrin agonist Mn2þ (1 mM) or the agonist LA1 (15 mM).
Data shown are mean 5 SE (n ¼ 3–6 replicates per condition) and are
from one of at least three independent experiments. *p < 0.05, ***p <
0.0001, ns ¼ not significant.
FIGURE 2 SCFS setup. Cartoon depiction of the experimental setup.
A cell was immobilized on a tissue culture dish and the CD11b/CD18
ligand ICAM-1 was used to functionalize the AFM cantilever. The cartoon
schematic also shows the principal events during an AFM force mea-
surement: i), approach of the ICAM-1 functionalized AFM cantilever
to an immobilized cell, ii), contact between the AFM cantilever tip and
the cell, iii), retraction of the cantilever tip, from the cell surface, and iv),
tether extraction during retraction of the cantilever tip. The gray trace
was recorded during cantilever approach, whereas the black trace was
recorded during retraction of the cantilever. To see this figure in color, go
online.
2520 Celik et al.cytoskeleton (29,37). Additionally, as has been shown previ-
ously, because the transfected integrin CD11b/CD18 is the
only b2 integrin expressed on the surface of K562 CD11b/
CD18 cells and since the K562 CD11b/CD18 cells constitu-
tively express the WT CD11b/CD18 in a low affinity state
(as in normal leukocytes) (29,37), these cells provide an
ideal live cell system to examine the effects of CD11b/
CD18 activation by various agonists (20,37). The ligand
ICAM-1 was immobilized on the surface of multiwell mi-
crotiter plates and K562 CD11b/CD18 cells were added to
the wells of the plates along with various agonists. The cells
showed minimal basal adhesion to immobilized ICAM-1 in
the presence of physiologic divalent cations (Ca2þ plus
Mg2þ, each at 1 mM) over the control cells incubated in
the absence of divalent ions (EDTA) (Fig. 1 C). Expectedly,
the agonists Mn2þ and LA1 significantly increased adhesion
of K562 CD11b/CD18 cells to ICAM-1.
Next, we used the K562 CD11b/CD18 cells in an AFM
setup to directly measure the adhesive interaction between
CD11b/CD18, upon activation with the two types of ago-
nists, and the immobilized ICAM-1. Fig. 2 illustrates theBiophysical Journal 105(11) 2517–2527AFM setup and the steps in the acquisition of the AFM force
measurements. ICAM-1 was coupled to the end of an AFM
cantilever and the K562 CD11b/CD18 cells were placed in a
tissue culture dish. In this experiment, during the approach
trace, the ICAM-1 functionalized AFM cantilever was low-
ered using a piezoelectric translator onto the surface of the
cells. Following the tip-cell contact, continued expansion
of the piezoelectric element pressed the flexible cantilever
against the cells that resulted in an upward deflection of
cantilever, which was continuously monitored to record
mechanical force acting on the system at a given moment.
Upon retraction of the piezoelectric translator, bonds
formed between CD11b/CD18 and ICAM-1 resulted in a
downward deflection of the cantilever. Cell adhesion was
characterized using three parameters derived from AFM
measurements: 1), the work of detachment 2), the detach-
ment force and 3), detachment distance. The work of
detachment is work done by the cantilever to detach the
tip from the cell and was determined by integrating force
over the distance curve. The detachment force is the
maximum force generated by the cantilever to induce cell
separation and the detachment distance is the distance
over which the cantilever remained in contact with the
cell. As shown in a series of traces in Fig. 3 A, activation
of CD11b/CD18 with the nonspecific agonist Mn2þ and
with the CD11b/CD18-agonist LA1 increased adhesion of
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FIGURE 3 LA1 increases the work of deadhe-
sion. (A) A series of representative AFM force
curves carried out under identical conditions
with K562 CD11b/CD18 cells interacting with
ICAM-1 coated onto an AFM tip. The traces are
from measurements carried out in buffers contain-
ing EDTA (10 mM), Ca2þ and Mg2þ ions (1 mM
each), Mn2þ ions (1 mM), or LA1 (15 mM). (B)
Histogram showing the work of detachment of
K562 cells expressing CD11b/CD18 (K562
CD11b/CD18) from ICAM-1 in the presence of
EDTA (10 mM), Ca2þ and Mg2þ ions (1 mM
each), the agonist Mn2þ ions (1 mM), or the
agonist LA1 (15 mM). Data shown are mean 5
SE (n ¼ 9 cells per condition). ***p < 0.0001, ns ¼ not significant. (C) Histogram showing quantitation of the detachment force required to detach
K562 CD11b/CD18 cells from ICAM-1 functionalized AFM cantilever in the presence of the control Ca2þ and Mg2þ ions (1 mM each), agonist Mn2þ
ions (0.1 mM), or the agonist LA1 (15 mM). Data shown are mean 5 SE (n ¼ 9 cells per condition). *p < 0.05, ***p < 0.0001, ns ¼ not significant.
CD11b Agonists Induce Membrane Tethers 2521K562 CD11b/CD18 cells to ICAM-1, as compared to cells
incubated with divalent metal ion chelator EDTA that sup-
presses integrin ligand binding. This is evidenced by the
larger maximum force required to detach the tip in the
agonist-treated cells.
Fig. 3, B and C, show that the work of detachment and
detachment force of K562 CD11b/CD18 cells to ICAM-1
under basal, physiologic concentration of Ca2þ and Mg2þ
cations were both significantly higher than the correspond-
ing values from cells treated with EDTA, where no integ-
rin-mediated adhesion was detected in the conventional
adhesion assay (Fig. 1 C). As predicted by the conventional
adhesion assay, both small molecule agonist LA1 and non-
physiological adhesion promoter, Mn2þ, significantly
enhanced the work of detachment and detachment force
of CD11b/CD18 expressing K562 cells to ICAM-1, as
compared to the cells adhering under the basal condition
(1 mM each of Ca2þ and Mg2þ cations). To test the speci-
ficity of the interaction between ICAM-1 and CD11b/
CD18 in our assay system, we also conducted similar mea-
surements on the nontransfected, parental K562 cell line
(Fig. S1 in the Supporting Material). In all test conditions
performed on the K562 cells (EDTA, Ca2þ and Mg2þ,
Mn2þ, and LA1), the detachment force and work of detach-
ment were significantly less than the observed values with
activated K562 CD11b/CD18 cells and were similar to
the levels obtained with K562 CD11b/CD18 cells treated
with EDTA (basal level). These control measurements
ensured that most of the unbinding events seen in the force
curves of the CD11b/CD18 expressing K562 cells were
due to the specific adhesive interaction between CD11b/
CD18 and ICAM-1. Thus, the results presented here suggest
that LA1 significantly increases the energy required for
detachment.
To determine if the area of tip-cell contact is the same for
the different experimental condition, Young’s modulus of
cells were measured (Fig. S2). Because cells treated with
Mn2þ were stiffer than cells under basal condition or treated
with LA1, the area of tip-cell contact at constant indentationis less for the Mn2þ-treated cells. The addition of agonist
LA1 did not significantly change Young’s modulus of
K562 CD11b/CD18 cells, as compared to cells in basal,
control conditions (Caþ2/Mgþ2). However, the addition of
agonist Mn2þ made the cells stiffer, an observation that is
consistent with published results (38). For a given indenta-
tion force, an increase in Young’s modulus reduces the
contact area and the number of the bonds formed. Our force
measurements revealed that there was a significant increase
in cell adhesion in the presence of Mn2þ even though the
contact area was reduced.LA1 increases cell adhesion via long membrane
tethers
A closer examination of the AFM cell adhesion measure-
ments revealed that the ICAM-1 functionalized AFM canti-
lever detached from the K562 CD11b/CD18 cell surface via
a series of ruptures as seen by the sharp vertical transitions
in the retraction curve (Fig. 3 A). Each rupture, denoted by
an arrow in Fig. 2, corresponds to the breakage of at least
one single bond between the integrin CD11b/CD18 and
ICAM-1. As reported previously, the AFM measurements
also revealed two distinct types of connections in integrin-
mediated cell adhesion: 1), cytoskeletal (CSK)-anchored
and 2), membrane-tethered bonds (39). The CSK-anchored
integrins are bound to the cellular cytoskeleton such that
the anchor bond strength is greater than the strength of the
adhesive bond between CD11b/CD18 and ICAM-1. Conse-
quently, as the ICAM-1 functionalized AFM cantilever is
withdrawn from the cell surface, the adhesive bond between
CD11b/CD18 and ICAM-1 unbinds before the CSK-
anchors rupture. Thus, the unbinding of CSK-anchored
CD11b/CD18-ICAM-1 complexes, which typically
occurred during early cell detachment, is coupled to the
extension of the elastic cytoskeletal elements and is pre-
ceded by an increase in the pulling force (e.g., r1, r2, and
r3 in Fig. 2). By contrast, the membrane-tethered integrins
are not anchored to the cytoskeleton or are only weaklyBiophysical Journal 105(11) 2517–2527
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2522 Celik et al.associated with it, such that this weak cytoskeletal associa-
tion breaks before the adhesive interaction between CD11b/
CD18 and ICAM-1. In such a case, membrane tethers were
formed when the integrins were pulled from the cell, see
Fig. 5 C. Due to the viscous properties of the membrane
tethers, membrane-tethered CD11b/CD18:ICAM-1 ruptures
exhibit a long constant force plateau before its dissociation
(e.g., r4, r5, and r6 in Fig. 2). Fig. 4 reveals that stimulation
of K562 CD11b/CD18 cells with Mn2þ increased the occur-
rence of CSK-anchored ruptures and membrane-tethered
ruptures by the factors of 1.5 and 4, respectively, over cells
incubated with physiologic 1 mM Ca2þ and Mg2þ ion con-
taining buffer. This result was expected because Mn2þ ions
activate all of the integrins on the cell surface regardless of
their anchorage type. Activation of CD11b/CD18 on K562
cells with LA1, similar to its stimulation with Mn2þ ions,
also showed increased activation of the membrane-tethered
integrins, which resulted in a fourfold increase in the num-
ber of tether bond ruptures, as compared to the tether bond
ruptures in the control Ca2þ and Mg2þ cells. However,
surprisingly, the agonist LA1 did not affect the occurrence
of CSK-anchored ruptures in these measurements, as was
observed with the Mn2þ-treated cells. A comparison
between the fraction of CSK-bonds and membrane tether
bonds between the Mn2þ and LA1 conditions clearly shows
that LA1 increases cell adhesion via a mechanism distinct
from Mn2þ and that it primarily mediates its adhesive
effects by increasing the number of membrane tether bonds
(Fig. 4 B).
During the retraction of the ICAM-1 functionalized canti-
lever from LA1-treated K562 CD11b/CD18 cells, we alsoBA
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FIGURE 4 LA1 mediates adhesion of CD11b/CD18 cells via membrane
tether bonds. (A) A histogram showing quantitation of the number and the
type of ruptures (CSK-bonds and membrane tether bonds) during the
detachment of CD11b/CD18 expressing K562 cells from ICAM-1 function-
alized AFM cantilever in the presence of physiologic Ca2þ and Mg2þ ions
(1 mM each), Mn2þ ions (1 mM), or LA1 (15 mM). Data shown are mean5
SE (n ¼ 9 cells per condition). ***p < 0.0001, ns ¼ not significant. (B) Pie
charts from the data presented in 4A showing the relative percentage of
CSK bond ruptures versus membrane tether bond ruptures during the
detachment of K562 CD11b/CD18 cells from ICAM-1 in cells stimulated
with agonists Mn2þ ions or LA1.
Biophysical Journal 105(11) 2517–2527observed that the cell is highly stretched, with elongations
of several microns, possibly stemming from tether forma-
tions (40). Quantitation of the distance required to detach
ICAM-1 functionalized AFM cantilevers from the K562
CD11b/CD18 cells under various conditions showed that
the detachment distance increased significantly when the
cells are activated with LA-1, as compared to the nonacti-
vated control cells. However, it remained unchanged for
cells activated with Mn2þ ions over nonactivated cells
(Fig. 5 A). The detachment time also increased in LA1-acti-
vated cells, but not Mn2þ activated cells, as compared to the
nonactivated cells. To visualize the long tethers, K562
CD11b/CD18 cells were transfected with a membrane-
bound marker conjugated to a GFP (the BacMam 2.0
CellLight Plasma Membrane-GFP marker) and the cells
were placed on ICAM-1-coated surfaces. Confocal imaging
of the cells showed long membrane tethers when a mechan-
ical force was applied to displace the cells activated with
LA1 (Fig. 5 C) versus the cells at rest (Fig. 5 B). Taken
together, these results suggest that the mechanism of LA1-
mediated increased in cell adhesion might be distinct from
that of the nonspecific integrin agonist Mn2þ ions and that
the agonist LA1 primarily mediates its adhesive effects by
increasing the number of membrane tether bonds versus pri-
marily the CSK-bond mediated increase in adhesion im-
parted by the Mn2þ ions.C
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FIGURE 5 The agonist LA1 increases membrane tethers. (A) A histo-
gram showing quantitation of the distance required to detach CD11b/
CD18 expressing K562 cells from ICAM-1 functionalized AFM cantilever
and the detachment time in the presence of control physiologic Ca2þ and
Mg2þ ions (1 mM each), agonist Mn2þ ions (1 mM), or the agonist LA1
(15 mM). Data shown are mean 5 SE (n ¼ 9 cells per condition).
***p < 0.0001, ns ¼ not significant. (B and C) Confocal microscopy
images of membrane tethers on LA1-activated K562 CD11b/CD18 cells.
K562 CD11b/CD18 cells transfected with a membrane-bound GFP marker
(CellLight Plasma Membrane-GFP, green) were placed on ICAM-1 coated
surfaces and were either not disturbed (B) or a mechanical force was applied
to displace the cells activated with LA1 (15 mM) in the direction from left
to right (C). A representative fluorescent image (C) revealed presence of
increasing number of long membrane tethers on the affected cells. Scale
bar represents 20 mm.
CD11b Agonists Induce Membrane Tethers 2523LA1 increases CD11b/CD18-dependent
neutrophil adhesion via tether bonds
CD11b/CD18 is highly expressed on neutrophils and medi-
ates the various biological functions of these cells. To
examine the biophysical mechanism of how LA1 mediates
its effects on the adhesion and migration of primary neutro-
phils, we used murine neutrophils in our cell force spectros-
copy setup. Because, under basal conditions, neutrophils
express significant levels of b2 integrin CD11a/CD18
(LFA-1, aLb2) and CD11b/CD18 (27), and since ICAM-1
is also a ligand for CD11a/CD18, we decided to use neutro-
phils from LFA-1 knock out animals (LFA-1/) in these
studies so as to solely focus on the specific CD11b/CD18:
ICAM-1 interaction. As expected, in adhesion assays, the
LFA-1/ neutrophils showed significantly enhanced adhe-
sion to immobilized ICAM-1 upon stimulation with agonists
Mn2þ ions or LA1, as compared to the cell adhesion under
basal, physiologic buffer conditions (Ca2þ and Mg2þ ions)
or in the presence of EDTA (Fig. 6 A). WT B6 neutrophils
showed similar results (Fig. S3 A).
Increasing CD11b/CD18-mediated cell adhesion with
LA1 decreases neutrophil migration and chemotaxis (20).
Both murine WT B6 neutrophils (Fig. S3, B and C), and
the LFA-1/ neutrophils (Fig. 6, B and C), showed signif-
icantly reduced lateral migration in response to a gradient of
chemokine peptide fMLP in the presence of agonists Mn2þ
ions or LA1 as compared to their migration under basal,
physiologic buffer conditions (Ca2þ and Mg2þ ions). Neu-
trophils, in response to chemokine signaling, polarize and
form distinct front edge (lamellipodia) and a trailing/rear
edge (uropod) to start migration (7,41). A forward migration
of the cell involves uropod elongation, via long membrane
tethers, and subsequent retraction (42) and increasing integ-
rin-mediated cell adhesion results in delayed uropod dead-
hesion and long membrane tethers (43). Previously, we
determined that the neutrophils chemotaxing in the presenceCBA
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overlay plots were created from the outlines of migrating cells at various time po
ment is from bottom to the top. Scale bar represents 14 mm. (C) A bar graph show
quantitative analyses of the data shown in 6B. Data shown are mean5 SE (n ¼of LA1 also show elongated tethers at the uropods (20), sug-
gesting increased number and/or length of membrane
tethers as a potential mechanism for how the agonist LA1
might be mediating its effects on neutrophil migration. To
investigate this further, we used AFM to quantitatively mea-
sure the effects of agonists Mn2þ and LA1 on enhanced
anchorage of neutrophil cell-surface expressed CD11b/
CD18 to AFM tip immobilized ICAM-1. As with K562
CD11b/CD18 cells, the incubation of LFA-1/ neutrophils
with nonspecific integrin agonist Mn2þ or with the CD11b/
CD18 agonist LA1 resulted in a similar increase in the
detachment energy of LFA-1/ neutrophils to ICAM-1
(~3.5-fold), as compared to the detachment energy observed
under basal, physiologic buffer conditions (Ca2þ and Mg2þ
cations) (Fig. 7 A). Like K562 CD11b/CD18 cells, the LA1-
stimulated neutrophils were also highly stretched, with
increased membrane elongations, likely due to increased
tether formations. Quantitation of the distance required to
detach the ICAM-1 coated AFM cantilever tips from the
LFA-1/ neutrophils and the detachment time also showed
that the detachment distance (and time) increased signifi-
cantly upon cell activation with LA-1, although little
such increase is seen upon activation with Mn2þ ions
(Fig. 7 B). Analysis of the force required for the tip detach-
ment (detachment force, Fig. 7 C) showed that integrin acti-
vation with either Mn2þ or LA1 increased the detachment
force required for the tip release, as compared to the nonac-
tivated condition. However, although activation with Mn2þ
resulted in a large increase in the force required, cells acti-
vated with LA1 required a substantially reduced level of
detachment force, confirming a stronger interaction between
the Mn2þ activated CD11b/CD18 and ICAM-1. A detailed
analysis of the AFM profiles again revealed that, like with
K562 CD11b/CD18 cells, the agonist Mn2þ significantly
increased the CSK-anchored ruptures over the cells incu-
bated with physiologic 1 mM Ca2þ and Mg2þ ion20
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FIGURE 6 LA1 increases LFA-1/ neutrophil
adhesion and decreases cell migration. (A) A histo-
gram showing adhesion of LFA-1/ neutrophils to
immobilized ICAM-1 (normalized to input cell
number) in the presence of EDTA (10 mM), phys-
iologic Ca2þ and Mg2þ ions (1 mM each), the
nonselective integrin agonist Mn2þ (0.1 mM), or
the agonist LA1 (15 mM). Data shown are
mean 5 SE (n ¼ 3 replicates per condition) and
are from one of at least three independent experi-
ments. ***p < 0.0001, ns ¼ not significant. (B)
Representative overlay plots showing analysis of
migrating LFA-1/ neutrophils in Zigmond
chambers in response to an fMLP gradient and in
media containing physiologic Ca2þ and Mg2þ
ions (1 mM each), the nonselective integrin agonist
Mn2þ (0.1 mM), or the agonist LA1 (15 mM). The
ints from time-lapse video microscopy. The directionality of the cell move-
ing the mean displacement of LFA-1/ neutrophils during migration after
75–100 cells per condition). ***p < 0.0001, ns ¼ not significant.
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FIGURE 7 LA1 increases the detachment energy and the rupture dis-
tance of neutrophils bound to ICAM-1. (A) A histogram showing the
work of detachment of LFA-1/ neutrophils from ICAM-1 in the presence
of physiologic Ca2þ and Mg2þ ions (1 mM each), the nonspecific agonist
Mn2þ ions (0.1 mM), or the agonist LA1 (15 mM). Data shown are
mean5 SE (n ¼ 6–9 cells per condition). ***p < 0.0001, ns ¼ not signif-
icant. (B) A histogram showing quantitation of the distance required to
detach LFA-1/ neutrophils from ICAM-1 functionalized AFM cantilever
and the detachment time in the presence of the control Ca2þ and Mg2þ ions
(1 mM each), agonist Mn2þ ions (0.1 mM), or the agonist LA1 (15 mM).
Data shown are mean 5 SE (n ¼ 6 to 9 cells per condition). ***p <
0.0001. (C) A histogram showing quantitation of the detachment force
required to detach LFA-1/ neutrophils from ICAM-1 functionalized
AFM cantilever in the presence of the control Ca2þ and Mg2þ ions
(1 mM each), agonist Mn2þ ions (0.1 mM), or the agonist LA1 (15 mM).
Data shown are mean 5 SE (n ¼ 6 to 9 cells per condition). ***p <
0.0001. (D) A histogram showing quantitation of the number and the
type of ruptures (CSK-bonds and membrane tether bonds) during the
detachment of LFA-1/ neutrophils from ICAM-1 in the presence of
Ca2þ and Mg2þ ions (1 mM each), Mn2þ ions (0.1 mM), or LA1
(15 mM). Data shown are mean 5 SE (n ¼ 6–9 cells per condition).
***p < 0.0001, ns ¼ not significant.
2524 Celik et al.containing buffer, whereas LA1 primarily increased the
occurrence of membrane tethers (Fig. 7 D). In all, the data
clearly suggest that the two types of agonists differentially
mediate CD11b/CD18 dependent adhesion to ICAM-1 and
that LA1 primarily mediates its effects by increasing the
number of membrane tethers.Biophysical Journal 105(11) 2517–2527DISCUSSION
LA1 is a member of a family of recently described small
molecules (termed leukadherins) that bind to the ligand
binding aA-domain of integrin CD11b/CD18, allosterically
stimulating CD11b/CD18-dependent cell adhesion and
reducing cell migration (20). LA1 administration in vivo
also results in increased neutrophil adhesion, significantly
decreased neutrophil migration, and tissue recruitment and
reduced inflammatory injury. This suggested that CD11b/
CD18 agonists are potential therapeutics for treating a
variety of inflammatory conditions in humans. However,
whether all integrin agonists, including known nonspecific
agonists, such as Mn2þ ions, could be potential therapeutics
or whether small molecule allosteric agonists, such as LA1,
use a different mechanism to modulate cell adhesion, is not
known and is important to investigate before such reagents
can be moved forward in the drug development pipeline.
Here, we used AFM-based single-cell spectroscopy mea-
surements to quantitatively establish the biophysical mech-
anism of how LA1 affects cell adhesion and migration.
Using an immortalized cell line (K562 cells) we found
that both, the known integrin agonist Mn2þ and the novel,
to our knowledge, small molecule agonist LA1, significantly
enhanced the binding and the detachment energy of CD11b/
CD18 to ICAM-1 over control, basal conditions. The AFM
measurements revealed that there are two populations of
CD11b/CD18 expressed on the surface of cells: one popula-
tion is anchored to the cytoskeleton (via CSK-anchored
bonds, where the strength of the integrin-cytoskeletal link-
age bond is greater than the strength of the linkage between
CD11b/CD18 and ligand (e.g., ICAM-1)) and a second pop-
ulation that is weakly associated with the plasma membrane
such that its cytoskeletal linkage unravels before the adhe-
sive bond between CD11b/CD18 and its ligand, thus form-
ing membrane tethers when pulled. These two populations
of CD11b/CD18 employ different biophysical mechanisms
for cell adhesion and migration. A closer examination of
the AFM-traces showed that LA1 primarily increased the
occurrence of membrane tether bonds, whereas Mn2þ addi-
tionally increased CSK-anchored bonds, suggesting that the
two types of agonists may differentially mediate the
increase in cellular adhesivity via integrins. Given that
CD11b/CD18 is highly expressed in neutrophils and medi-
ates a majority of its biological functions, we also investi-
gated the mechanism of how the two types of agonists
stimulate CD11b/CD18-mediated cell adhesion to
ICAM-1 in these primary cells. Additionally, as the neutro-
phils also express integrin LFA1, another cellular receptor
for ICAM-1 and an integrin that is highly homologous to
CD11b/CD18, we used neutrophils from LFA1 knockout
animals (LFA1/), in addition to the WT neutrophils, to
focus solely on the CD11b/CD18:ICAM-1 interaction. In
static adhesion assays, both Mn2þ and LA1 significantly
increased the adhesion of neutrophils to immobilized
CD11b Agonists Induce Membrane Tethers 2525ICAM-1 and the AFM measurements confirmed that both
also equally increased the detachment energy of CD11b/
CD18 to ICAM-1 over nonactivated cells. However, as
with K562 CD11b/CD18 cells, LA1 activated cells showed
much longer detachment distances and took a longer time to
detach the ICAM-1-coated AFM tips, but showed signifi-
cantly reduced detachment force, as compared to the
Mn2þ stimulated cells. Comparison of the type of cellular
attachment confirmed that, like with K562 CD11b/CD18
cells, LA1 primarily increased the number of membrane-
tether bonds to increase CD11b/CD18:ICAM-1 binding,
whereas Mn2þ additionally induced the CSK-anchored
bonds.
Differences between LA1 and Mn2þ activation mecha-
nisms can be rationalized in a model where the majority
of the inactive integrin CD11b/CD18 molecules of the
resting cells are mobile and do not strongly associate with
the cytoskeleton. For example, it was recently shown that
95% of LFA1 in THP-1 cells is primarily organized in nano-
clusters and is highly mobile (44). Therefore, our proposed
model for the mechanism of CD11b activation via the two
types of agonists as follows (schematically depicted in
Fig. 8). LA1 specifically activates resting integrins, which
are highly mobile and are primarily not associated with
the cellular cytoskeleton, to bind to ligand ICAM-1, thereby
enhancing the lifetime but not the force of the adhesive bond
and causing tethers to form. The nonspecific agonist Mn2þ,
by altering the extracellular CD11b/CD18 conformation to
a fully active, highly adhesive state, additionally enhanced
integrin-cytoskeletal linkage. We recently noted, using
conformation-sensitive antibodies, that LA1-mediated
CD11b/CD18 activation results in local, rather than global,
conformational changes in the integrin dimer (21), whereas
activation with Mn2þ provided global conformational
changes, consistent with the observations here. Bakker
et al. also noted a reduction in LFA-1 motility upon cell acti-FIGURE 8 LA1 mediates its effects on CD11b/CD18-dependent cell adhesio
effect of LA1 binding and CD11b/CD18 activation showing that LA1 binding
adhesion of CD11b/CD18-expressing cells to ICAM-1 via membrane tether bovation. This would explain the increase in the number of
CSK ruptures in the AFM force measurements. Addition-
ally, it has been reported that integrins in high affinity
conformation bind their ligands primarily via cytoskeletal
linkages, whereas such a CSK-linkage is not needed for
integrin priming and adhesion mediated via intermediate
affinity conformation of integrins (45,46). This would sug-
gest that LA1-mediated CD11b/CD18 activation leads to
integrin priming and conversion to an intermediate affinity
conformation, also consistent with our recent findings using
conformation-specific antibodies (21). The results indicate
that these two types of agonists differentially transduce me-
chanical signals to inside the cells.
In addition to an increase in the number of tethers formed
upon LA1 treatment of K562 CD11b/CD18 cells and the
neutrophils, we also noted that there is an increase in the
detachment distance, which we attribute to an increase in
the length and lifetime of the last membrane tether to
rupture. The lifetime of this last tether increased from
1.5 s to 3.5 s after LA1 treatment. The lifetime of these
tethers are significantly longer than expected for a mem-
brane tether supported by a single CD11b/CD18:ICAM-1
complex at the pulling force of 25 pN. We estimate (based
on derivation in Fig. S4 (47,48);) that there are between 7
and 20 CD11b/CD18:ICAM-1 complexes supporting the
last tether of resting and LA1 treated cells, respectively.
Interestingly, the detachment distance of Mn2þ-activated
cells (~6 um) was significantly shorter than measurements
from LA1-treated cells (~12 um). We attribute this differ-
ence to the strong coupling of CD11b/CD18 to the cytoskel-
eton, which reduces the number of CD11b/CD18 available
for elongation of membrane tethers. Consequently, Mn2þ-
activated neutrophils formed strong CSK bonds with large
detachment forces (Fig. 7) that were difficult for a migrating
cell to rupture; hence they were less mobile (Fig. 6 C). LA1-
treated cells formed long tethers, but their detachment forcen by increasing the membrane tether bonds. A cartoon model depicting the
to the ligand binding aA-domain of CD11b/CD18 primarily enhances the
nds and not the cytoskeletal linkages.
Biophysical Journal 105(11) 2517–2527
2526 Celik et al.was weaker than that of Mn2þ-treated cells. Hence, it was
easier for LA1-treated cells to overcome this traction and
cells were more motile (Fig. 6 C).
In summary, we show here that different agonists of
CD11b/CD18 use different mechanisms to couple integrin
activation to the cellular machinery. Agonist LA1 primarily
increased the number of integrin membrane-tether bonds,
whereas agonist Mn2þ additionally induced the integrin-
cytoskeletal linkages. In vivo, the formation of these long
membrane tethers may provide the structural units for the
arrest of rolling leukocytes within the blood vessels.SUPPORTING MATERIAL
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